1Farde L, Wiesel FA, Halldin C, et al. Central D2 dopamine receptor occupancy in schizophrenic patients treated with anti psychotic drugs[J]. Arch Gen Psychiatry, 1988,45 (1) : 71 - 76.
2Kapur S,Zipursky R,Jones C,et al. Relationship between do pamine D2 occupancy, clinical response, and side effects: a double--blind PET study of first episode schizophrenia[J]. Am J Psychiatry,2000,157(4) :514-520.
3Sanofi--Aventis. Summary of product characteristics. Solian [J]. Available at: http://emc, medicines, org. uk/2008 (ac- cessed on 17 March 2009).
4Puech A,Fleurot O,Rein W. Amisulpride and atypical antip sychotic,in the treatment of acute episodes of schizophrenia: a dose--ranging study vs. haloperidol. The Amisulpride Study Group[J]. Acta Psychiatr Scand, 1998,98(1) :65-72.
5Stefan Leucht, Caroline Corves, Dieter Arbter. Second-- gener ation versus first--generation antipsychotic drugs for sehizo phrenia: a meta-analysis[J]. Lancet,2009,373:31-41.
6Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisul- pride. Amisulpride Study Group[J]. Am J Psychiatry, 1999, 156(4) :610-616.
7Deeks ED,Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression[J]. Drugs, 2008,68(8):1 115-1 137.
8Mortimer AM, Joyce E, Balasubramaniam K, et al. Treatment with amisulpride and olanzapine improve neuropsyehologicalfunction in schizophrenia[J]. Hum Psychopharmacol, 2007,22 (7) :445-454.
9Lecrubier Y, Boyer P, Turjanski S, et al. Amisulpride versus imipramine and placebo in dyslhymia and major depression. Amisulpride Study Group[J]. J Affect Disord, 1997,43(2): 95-103.
10Smeraldi E. Amisulpride versus fluoxetine in patients with dys- thymia or major depression in partial remission: a double blind,comparative study[J]. J Affect Disord, 1998,48(1): 47-56.
